Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Placebo/Veterans

Placebo for Veterans

1 paper and 7 clinical trials exploring placebo as a treatment for veterans.

CompoundComparator / Control

Placebo

Placebo is the most widely referenced comparator in psychedelic clinical research, appearing in over 500 trials. Understanding how placebos are designed, administered, and interpreted is essential to evaluating the evidence base for psychedelic-assisted therapies — and one of the field’s most contested methodological challenges.

Full Placebo profile
IndicationApproximately 1 in 10 veterans are diagnosed with PTSD and around 30% of veterans experience depression.

Veterans

Psychedelic treatments are emerging as promising therapeutic options for veterans dealing with mental health conditions, particularly post-traumatic stress disorder (PTSD) and treatment-resistant depression. Recent clinical trials highlight the efficacy of compounds such as MDMA and psilocybin in alleviating symptoms and improving overall quality of life.

Full Veterans profile

Academic Research

1 paper
Paywallindividual

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression

This secondary analysis of an open-label trial (n=15) examined a single 25 mg dose of psilocybin with psychological support in veterans with treatment-resistant depression, focusing on anxiety, quality of life, functioning, and PTSD symptoms. Improvements were observed across these measures, but most were no longer significant after accounting for concurrent improvements in depression.

Published
June 4, 2026
Journal
Journal of Affective Disorders
Authors
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A., Ellis, S., Ostacher, M., Aaronson, S., Suppes, T.

Clinical Trials

7 trials
WithdrawnPhase II

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

This Phase II, non-randomised, open-label, parallel-group trial (n=150) will study response to three neuroplasticity-enhancing interventions in civilian and Veteran adults (aged 18–69) at low, intermediate or high risk for self-harm. The study will evaluate clinical change in suicidal ideation (Scale of Suicidal Ideation from baseline to the post‑treatment visit at Month 6) and aim to characterise neurobiological and blood-based markers associated with risk and treatment response. Participants are allocated to one of three experimental arms: two sessions of fMRI neurofeedback targeting amygdala activity, an accelerated theta burst stimulation programme of 50 sessions delivered to the dorsolateral prefrontal cortex, or psilocybin‑assisted therapy comprising three preparation sessions, two psilocybin administration sessions and two integration sessions. Baseline and post‑treatment assessments include clinical measures, structural and functional MRI and blood sampling for circular RNA (circRNA); an artificial intelligence analytic team will use these multimodal data to develop predictive models of behavioural risk and treatment response.

Started
May 1, 2026
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07484906
Temporarily not availablePhase II

Department of Defense PTSD Adaptive Platform Trial – Intervention D – SLS-002

This Phase II randomised, quadruple-blind, placebo-controlled trial (n=200) will assess the safety and efficacy of intranasal SLS-002 (ketamine, 78mg) for post-traumatic stress disorder (PTSD) in active-duty service members and veterans.

Started
June 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06816433
RecruitingPhase II

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

This randomized, double-blind, single-site Phase II trial (n=40) will investigate MDMA-assisted therapy’s safety and preliminary efficacy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in veterans with at least moderate PTSD severity.

Started
October 1, 2023
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT05790239
CompletedPhase NA

Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

This observational cohort study (n=30) evaluated the safety and efficacy of Ibogaine-Magnesium Therapy in veterans with sequelae of repeated blast exposure.

Started
November 15, 2021
Type
observational
Blinding
none
Randomized
No
Registry ID
NCT04313712
CompletedPhase II

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Phase II randomised, quadruple-blind parallel trial (n=75 actual) of IV ketamine (0.5 mg/kg weekly ×3) vs active placebo (midazolam 0.045 mg/kg) combined with Prolonged Exposure therapy for Veterans with PTSD.

Started
March 9, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04560660
CompletedPhase II

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

Randomised, parallel RCT (n=62) in Veterans with treatment‑resistant depression comparing six IV ketamine infusions (0.5 mg/kg) over 12 days versus a single IV ketamine infusion (0.5 mg/kg) preceded by five midazolam infusions (0.045 mg/kg) as an active comparator.

Started
April 1, 2015
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT02360280

Explore further

Search all Placebo papers Search all Veterans trials Full Placebo profile Full Veterans profile